NTLA — Intellia Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $2.42bn
- $1.63bn
- $36.28m
- 54
- 12
- 36
- 26
Annual cashflow statement for Intellia Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -99.5 | -134 | -268 | -474 | -481 |
| Depreciation | |||||
| Non-Cash Items | 11.4 | 20.5 | 58.9 | 187 | 131 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -20.7 | 57.5 | -22.9 | -53.9 | -52.5 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -103 | -49.9 | -225 | -333 | -394 |
| Capital Expenditures | -6.79 | -3.58 | -12.8 | -13.6 | -14 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 32 | -211 | -538 | 174 | -17.4 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 25.2 | -214 | -551 | 160 | -31.3 |
| Financing Cash Flow Items | 72.3 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 76.4 | 372 | 737 | 583 | 130 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -1.63 | 107 | -39.1 | 410 | -295 |